Switching from SRIs to Agomelatine for OCD Treatment
Author Information
Author(s): Michele Fornaro
Primary Institution: University of Genova, Department of Psychiatry, Genoa, Italy
Hypothesis
Can switching from serotonin reuptake inhibitors (SRIs) to agomelatine improve symptoms in patients with refractory obsessive-compulsive disorder (OCD)?
Conclusion
Agomelatine may be beneficial for some patients with SRI-refractory OCD, particularly those with circadian rhythm impairments.
Supporting Evidence
- Three out of six patients showed a significant reduction in Y-BOCS scores after switching to agomelatine.
- No relevant side effects were observed in most patients during the study.
- Patients with circadian rhythm impairments showed more significant improvements.
Takeaway
Some people with OCD who didn't get better with their usual medicine felt better after switching to a new medicine called agomelatine.
Methodology
Six patients with refractory OCD were switched from SRIs to agomelatine 50 mg/day and followed for 12 weeks, with Y-BOCS scores measured monthly.
Potential Biases
Potential biases due to the small, heterogeneous sample and subjective assessments.
Limitations
Small sample size, lack of control group, and short follow-up period limit the validity of the findings.
Participant Demographics
Patients included a mix of genders and ages, with various comorbidities.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website